Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-25T11:42:46.053Z Has data issue: false hasContentIssue false

Assessing Mupirocin Resistance in MRSA Isolates in Hospitals in Cleveland, OH and Detroit, MI

Published online by Cambridge University Press:  16 September 2024

Taylor Yakubik
Affiliation:
Baylor Scott and White
Collin Telchik
Affiliation:
Department of Internal Medicine, Baylor Scott and White Medical Center, Temple, Texas
Andrea Grimbergen
Affiliation:
Baylor Scott & White
Chetan Jinadatha
Affiliation:
Central Texas Veterans Health Care System
Munok Hwang
Affiliation:
Central Texas VA Research Foundation
Hosoon Choi
Affiliation:
Central Texas Veterans Health Care System
Curtis Donskey
Affiliation:
Cleveland VA Medical Center
Jennifer Cadnum
Affiliation:
Cleveland VA Medical Center
Sorabh Dhar
Affiliation:
Harper Unive Hosp
Piyali Chatterjee
Affiliation:
Central Texas Veterans Health Care System
Keith Kaye
Affiliation:
Rutgers Robert Wood Johnson Medical School

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a common pathogen responsible for nosocomial and community-acquired infections with high morbidity and mortality1. MRSA nasal colonization is a major risk factor for developing infection in the hospital setting2,3. Decolonization of MRSA carriers is a strategy to decrease recurrence or to prevent new MRSA infections3,4. Decolonization with nasal mupirocin 2% and chlorhexidine baths has been shown to decrease the risk of MRSA infection after hospital discharge3. Mupirocin is an RNA synthetase inhibitor with activity against MRSA5. Resistance of MRSA isolates to mupirocin has been described previously6. As topical disinfectants play a crucial role in prevention of MRSA infection in a variety of settings, it is important to monitor the emergence of resistance. The goal of this study was to determine the prevalence of mupirocin resistance among MRSA samples isolated from two different regions in the United States (U.S). Methods: Our study had a total of 474 MRSA samples that were obtained from hospitals in Detroit, MI (287 samples) and Cleveland, OH (187 samples). After whole genome sequencing using NextSeq (Illumina Inc., CA) platform the data was analyzed using ResFinder 4.1, to identify antimicrobial resistance which can be either acquired or chromosomally mediated mutations. To visualize the presence of genes of interest the resistance genes were tallied on a spread sheet. Results: Mupirocin resistance gene was detected in five of 287 (1.74%) MRSA samples from the Detroit hospitals, all of which were associated with the mupA gene. Samples collected from the Cleveland area hospital demonstrated mupirocin resistance in seven samples of 187 (3.74%), all associated again with the mupA gene. One sample from the Detroit group showed resistance to both mupirocin and chlorhexidine. Conclusions: Prevalence of mupirocin resistance gene varied between the two hospital locations. Resistance to mupirocin has been documented in association with mutations in the mupA gene as well as chromosomal point mutations that can lead to either low or high-level resistance7,8. Although the mechanisms are not fully clear, mupA gene has been associated with high-level resistance9. Mupirocin resistance among MRSA isolates has increased over time9. MRSA infections remain an important etiology of nosocomial and community-acquired infections and common practice to combat this issue is universal decolonization with mupirocin10. It is critical to understand and monitor for development of mupirocin resistance as mupirocin remains one of the most effective tools to prevent invasive infection with MRSA in many patient populations.

Type
MRSA/VRE
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America